MSD’s Keytruda wins expanded FDA combo approval in cervical cancer
15 Jan 2024
Clinical ResultDrug ApprovalPhase 3AcquisitionImmunotherapy
Preview
Source: Pharmaceutical Technology
Nearly all cervical cancer cases are linked to infection with high-risk human papillomaviruses (HPV). Image credit: Shutterstock/Naeblys.
The US Food and Drug Administration (FDA) has expanded Keytruda’s use (pembrolizumab) in combination with chemoradiotherapy to certain advanced types of cervical cancer.
Patients with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer will now be eligible for MSD’s blockbuster immunotherapy.
MSD states the FDA nod means its drug is the only anti-PD-1 therapy and chemoradiotherapy combination approval for newly diagnosed US patients with high-risk locally advanced cervical cancer, according to a 12 January press release.
Keytruda already has two FDA approvals in cervical cancer for patients who express PD-L1 tumours. One as a first-line therapy in combination with chemotherapy, with or without bevacizumab, the other as a single agent second-line therapy in patients for whom chemotherapy has not worked.
The agency based its decision on results from the Phase III KEYNOTE-A18 trial (NCT04221945). Patients who received the combo therapy demonstrated a progression-free survival (PFS) – the risk of disease progression or death was reduced by 41%. MSD said the FIGO 2014 Stage III-IVA disease sub-group was the main driver of PFS improvement. The trial enrolled 1,0060 cervical cancer patients who had not received surgery, radiation, or systemic therapy for treatment.
Cervical cancer is the fourth most common cancer in women globally, according to the World Health Organisation. Most cases are linked to infection with high-risk human papillomaviruses (HPV).
MSD Research Laboratories’ global clinical development vice president Dr. Gursel Aktan said: “This approval provides newly diagnosed patients with an anti-PD-1-based treatment option that has the potential to reduce the risk of disease progression or death compared to chemoradiotherapy alone.”
Keytruda is set to lose its patent protection in 2028, however, with the market likely to become flooded with lower-cost biosimilars, echoing what happened with AbbVie’s Humira (adalimumab).
GlobalData’s Pharma Intelligence Centre forecasts peak sales of $33.7bn in 2028.
GlobalData is the parent company of Pharmaceutical Technology.
MSD has been busy shoring up future revenue streams in oncology as a result, with the big pharma acquiring T-cell engager specialist Harpoon Therapeutics for $680m in January 2024. In October 2023, the company also entered an agreement to develop and commercialise three of Daiichi Sankyo’s antibody drug conjugate (ADC) in a deal that could be worth up to $22bn.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.